Balance Sheet (Annual)

CVSI / CV Sciences, Inc. Short Interest

CVSI / CV Sciences, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash - - - - 518 782 2,013
    Restricted Cash Current - - - - - - -
    Accounts Receivable Net Current - - 1,430 282 871 360 1,508
    Inventory Net - - 2,473 11,666 14,134 2,852 2,823
    Prepaid Expense And Other Assets Current - - - - - - -
    Assets Current 3 - 8,056 16,806 16,592 4,821 7,935
    Inventory Noncurrent - - - - - 6,479 5,667
    Other Assets Noncurrent - - - - - - -
    Property Plant And Equipment Net - - 214 516 440 243 2,083
    Finite Lived Intangible Assets Net - - 3,356 2,535 5,620 3,872 3,836
    Goodwill - - 1,856 1,856 4,644 2,788 2,788
  Assets - - 14,232 21,740 27,295 18,592 22,710
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable Current 20 - 25 546 659 524 678
    Accrued Liabilities Current - - 223 118 523 378 1,932
    Convertible Debt Current - - - - 882 1,898 610
    Notes Payable Current - - - - - - -
    Liabilities Current 41 - 423 665 2,453 3,149 3,336
  Liabilities Noncurrent
    Unsecured Long Term Debt - - - - - 679 850
    Deferred Credits And Other Liabilities Noncurrent - - - - - - -
    Deferred Tax Liabilities Noncurrent - - - - 1,556 1,556 1,075
  Liabilities - - 5,925 665 4,009 5,384 6,329
Commitments And Contingencies - - - - - - -
Stockholders Equity
  Preferred Stock Value - - 0 0 0 0 0
  Common Stock Value 1 - 2 3 5 6 9
  Additional Paid In Capital 60 - 10,750 24,828 39,271 43,333 51,400
  Retained Earnings Accumulated Deficit -99 - -2,444 -3,756 -15,989 -30,131 -35,028
  Stockholders Equity -38 - 8,307 21,075 23,286 13,208 16,381
  Liabilities And Stockholders Equity 3 - 14,232 21,740 27,295 18,592 22,710

Peers - Cannabis and Medical Marijuana Dispensaries (512227)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 126654102